ArticleBMC public health2025
Uptake of second dose measles containing vaccine and associated factors among children aged 24-35 months in central Ethiopia: a community based cross-sectional study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Uptake of the Second Dose of the Measles Vaccine and Its Determinants Among Children Aged Less Than 5 Years: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2025Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeasles is a highly contagious viral disease that remains a significant public health issue worldwide. Two doses of measles-containing vaccines are required to prevent it effectively. Evidence is limited on measles containing vaccination second-dose (MCV2) in Ethiopia in general, and in Merhabete district in particular. Therefore, this study aimed to assess the uptake of MCV2 and associated factors among children aged 24-35 months in Merhabete district, Central Ethiopia.
methodsA community-based cross-sectional study was conducted in Merhabete district, North Shoa zone, from June 1-30, 2022 on 732 children aged 24-35 months. The collected data was entered to EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable logistic regression models were used to identify factors associated with the uptake of MCV2. Adjusted odds ratios with 95%CI and P < 0.05 were used to measure the strength of association and declare statistically significant factors, respectively.
resultsThe uptake of MCV2 was 63.3% (CI: 60-67%). Knowledge of MCV2 schedule (AOR: 2.151, CI: 1.05, 4.40), institutional delivery (AOR: 3.50, CI: 1.58, 7.77), ≥ 4 antenatal care visits (AOR: 2.56, CI: 1.25, 5.23), availability of immunization card (AOR: 9.96, CI: 4.26, 23.30), and mother's age between 25 and 34 years (AOR: 2.95, CI: 1.30, 6.72) were statistically significant factors for the uptake of MCV2.
conclusionThe uptake of MCV2 in Merhabete District was lower than the measles elimination target. Number of antenatal visits 4 or more, place of delivery, knowledge of MCV2 schedule, immunization card availability, and maternal age were found to be statistically significant factors for the uptake of MCV2. Therefore, health decision makers better to strengthen periodic monitoring and evaluation of the implementation of the MCV2 delivery programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.